全文获取类型
收费全文 | 53766篇 |
免费 | 4987篇 |
国内免费 | 3147篇 |
专业分类
耳鼻咽喉 | 530篇 |
儿科学 | 539篇 |
妇产科学 | 646篇 |
基础医学 | 6967篇 |
口腔科学 | 1089篇 |
临床医学 | 6516篇 |
内科学 | 8195篇 |
皮肤病学 | 748篇 |
神经病学 | 2915篇 |
特种医学 | 2488篇 |
外国民族医学 | 37篇 |
外科学 | 6006篇 |
综合类 | 7676篇 |
现状与发展 | 7篇 |
一般理论 | 2篇 |
预防医学 | 3264篇 |
眼科学 | 1528篇 |
药学 | 5425篇 |
40篇 | |
中国医学 | 2664篇 |
肿瘤学 | 4618篇 |
出版年
2024年 | 42篇 |
2023年 | 682篇 |
2022年 | 1111篇 |
2021年 | 2482篇 |
2020年 | 1907篇 |
2019年 | 1801篇 |
2018年 | 1945篇 |
2017年 | 1658篇 |
2016年 | 1780篇 |
2015年 | 2577篇 |
2014年 | 3207篇 |
2013年 | 2894篇 |
2012年 | 4617篇 |
2011年 | 4711篇 |
2010年 | 2997篇 |
2009年 | 2457篇 |
2008年 | 3183篇 |
2007年 | 3052篇 |
2006年 | 2829篇 |
2005年 | 2576篇 |
2004年 | 1863篇 |
2003年 | 1701篇 |
2002年 | 1490篇 |
2001年 | 1193篇 |
2000年 | 1221篇 |
1999年 | 1149篇 |
1998年 | 641篇 |
1997年 | 679篇 |
1996年 | 541篇 |
1995年 | 461篇 |
1994年 | 381篇 |
1993年 | 274篇 |
1992年 | 336篇 |
1991年 | 249篇 |
1990年 | 216篇 |
1989年 | 194篇 |
1988年 | 162篇 |
1987年 | 142篇 |
1986年 | 110篇 |
1985年 | 96篇 |
1984年 | 53篇 |
1983年 | 53篇 |
1982年 | 28篇 |
1981年 | 27篇 |
1980年 | 15篇 |
1979年 | 24篇 |
1978年 | 13篇 |
1973年 | 11篇 |
1971年 | 9篇 |
1969年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
52.
53.
54.
Qianlai Luo Jonathan N. Hofmann Ruth M. Pfeiffer Cari M. Kitahara Minkyo Song Meredith S. Shiels 《International journal of cancer. Journal international du cancer》2023,153(1):64-72
In the United States, renal cell carcinoma (RCC) incidence and the prevalence of obesity, an established risk factor for RCC, have been increasing for several decades. RCC is more common among older individuals. We sought to quantify the contribution of excess adiposity to the rising incidence of RCC among individuals 60 years or older. National Institutes of Health-American Association of Retired Persons Diet and Health Study data (n = 453 859 participants, enrolled in 1995-1996, age at enrollment 50-71 years) were used to estimate multivariable-adjusted hazard ratios (HRs) for RCC across body mass index categories and HRs associated with smoking. Population attributable fractions (PAFs) were calculated using estimated HRs and annual overweight/obesity prevalence from the National Health Interview Survey (1985-2008). PAF estimates were combined with RCC incidence from Surveillance, Epidemiology and End Results-13 to calculate annual percent changes in RCC incidence attributable (and unrelated) to overweight/obesity. We found that between 1995 and 2018, among individuals aged 60 years and older, PAF for overweight/obesity increased from 18% to 29% for all RCCs. In comparison, the PAF for smoking declined from 12% to 9%. RCC incidence increased 1.8% per year (95% confidence interval [CI] 1.5%-2.1%) overall, while RCC incidence attributable to overweight/obesity increased 3.8% per year (95%CI 3.5%-4.2%) and RCC incidence unrelated to overweight/obesity increased 1.2% per year (95% CI 0.9%-1.4%). In conclusion, overweight/obesity appears to have contributed importantly to the rising incidence of RCC in the United States since the mid-1990s. Public health interventions focused on reducing overweight and obesity could help substantially in curbing this trend. 相似文献
55.
目的基于人类免疫缺陷病毒Ⅰ型(HIV-1)感染者外周血单个核细胞(PBMCs)中HIV-1总DNA和RNA定量检测结果对感染细胞内病毒的转录活性进行区分。方法采集2017年10月至2018年12月于哈尔滨医科大学附属第四医院感染科就诊的HIV-1感染者血液样本,分离PBMCs细胞,采用PCR荧光探针法对PBMCs细胞内HIV-1总DNA和RNA进行定量检测,并计算两者比值(Ratio)。根据Ratio值筛选出HIV-1转录活跃组样本和相对非活跃组样本,另外选择健康人PBMCs样本作为对照组。对3组样本进行基因转录组表达谱检测以及人口特征差异性检验,并对基因表达谱检测结果进行主成分分析以验证对3组样本病毒转录活性区分的准确性。结果从60例感染HIV-1患者的PBMCs样本中筛选出HIV-1转录活跃组样本(10例)和相对非活跃组样本(11例),另外选择6例健康人PBMCs样本作为对照组。其中转录活跃组样本Ratio值为165.2~738.93,平均为(339.27±189.68);相对非活跃组Ratio值为4.67~42.39,平均为(17.65±11.78)。转录活跃组和相对非活跃组样本间的CD4+T细胞计数(P=0.049)和Ratio值(P<0.001)差异均具有统计学意义;3组样本年龄(P=0.989)和性别(P=0.650)分布差异无统计学意义。对3组样本的PBMCs基因表达谱主成分分析结果显示:对照组与HIV-1感染者(包括转录活跃组和相对非活跃组)间区分明显。转录活跃组和相对非活跃组间有部分样本重合,同时结果也显示当HIV-1感染者的CD4+T淋巴细胞计数与健康人无显著差异时,其细胞内的基因表达与健康人接近。结论基于HIV-1总DNA和RNA定量检测结果及两者间比值可以较好地区分PBMCs内病毒转录活性。HIV-1感染细胞内部病毒的不同转录激活状况可导致其基因表达谱的异质性。 相似文献
56.
Yongfang Ma Ruyue Xu Xueke Liu Yinci Zhang Li Song Shuyu Cai Shuping Zhou Yinghai Xie Amin Li Weiya Cao Xiaolong Tang 《International journal of medical sciences》2021,18(6):1456
Background: Sorafenib, an oral multi-kinase inhibitor of rapidly accelerated fibrosarcoma; vascular endothelial growth factor receptor-2/3, platelet-derived growth factor receptor, c-Kit, and Flt-3 signaling, is approved for treatment of advanced hepatocellular carcinoma (HCC). However, the benefit of sorafenib is often diminished because of acquired resistance through the reactivation of ERK signaling in sorafenib-resistant HCC cells. In this work, we investigated whether adding LY3214996, a selective ERK1/2 inhibitor, to sorafenib would increase the anti-tumor effectiveness of sorafenib to HCC cells.Methods: The Huh7 cell line was used as a cell model for treatment with sorafenib, LY3214996, and their combination. Phosphorylation of the key kinases in the Ras/Raf/MAPK and PI3K/Akt pathways, protein expression of the cell cycle, and apoptosis migration were assessed with western blot. MTT and colony-formation assays were used to evaluate cell proliferation. Wound-healing assay was used to assess cell migration. Cell cycle and apoptosis analyses were conducted with flow cytometry.Results: LY3214996 decreased phosphorylation of the Ras/Raf/MAPK and PI3K/Akt pathways, including p-c-Raf, p-P90RSK, p-S6K and p-eIF4EBP1 activated by sorafenib, despite increased p-ERK1/2 levels. LY3214996 increased the anti-proliferation, anti-migration, cell-cycle progression, and pro-apoptotic effects of sorafenib on Huh7R cells.Conclusions: Reactivation of ERK1/2 appears to be a molecular mechanism of acquired resistance of HCC to sorafenib. LY3214996 combined with sorafenib enhanced the anti-tumor effects of sorafenib in HCC. These findings form a theoretical basis for trial of LY3214996 combined with sorafenib as second-line treatment of sorafenib-resistant in advanced HCC. 相似文献
57.
Lei Guo Changhua Wu Dan Song Liang Wang Jing Li Jiali Sun Yunkui Zhang 《Journal of vascular and interventional radiology : JVIR》2021,32(2):293-298
PurposeTo report the effectiveness and safety of transcatheter arterial sclerosing embolization (TASE) for the treatment of parotid infantile hemangiomas that did not respond appreciably to propranolol.Materials and MethodsA total of 21 infants (12 male and 9 female) with large propranolol-resistant infantile hemangiomas in the parotid region were enrolled in this study. During TASE, the feeding arteries of the lesions were embolized using pingyangmycin-lipiodol emulsion and polyvinyl alcohol particles (300–500 μm) to reduce the blood flow rate. All children were followed up as outpatients at 2 weeks and monthly thereafter. The curative effect was evaluated at the 1- and 3-month follow-up visits.ResultsNine lesions were located on the right side of the parotid gland, whereas 12 were located on the left side. The feeding arteries in all patients originated from branches of the external carotid artery. TASE was technically successful in all patients. The mean (± SD) maximal diameter of the hemangiomas significantly decreased from 6.50 cm ± 2.28 before treatment to 3.56 cm ± 1.84 at 1 month after TASE (P <. 05). Three months after TASE, the mean maximal diameter further significantly decreased to 1.94 cm ± 1.58 (P <. 05). During the follow-up period, 16 cases were rated as excellent and 5 as good; no recurrence or serious complications were noted. Minor side effects, such as slight pain, mild fever, and tissue swelling, were observed.ConclusionsTASE significantly decreased the size of the parotid hemangiomas with minor side effects during a short follow-up period. 相似文献
58.
59.
Inflammation Research - Studies have pivoted on the position of microRNAs (miRNAs) in knee osteoarthritis (KOA) but not the more specific function of miR-199-3p. Thus, this study is to uncover the... 相似文献
60.
目的 挖掘藏医治疗肝胆疾病的用药规律,寻找核心药组,并预测核心药组的潜在靶点,以探讨核心药组治疗肝胆疾病的作用机制。方法 收集藏医药典籍中治疗肝胆疾病处方,采用SPSS软件进行Apriori算法关联规则分析得到藏医治疗肝胆疾病的核心药组。检索中药系统药理学分析平台(TCMSP)、Therapeutic Target Database (TTD)、Genecards、Metascape等数据库进行基因本体(GO)和KEGG富集分析。结果 共纳入607首方剂,数据挖掘得到藏医治疗肝胆疾病的核心药组为蒂达-洪连-波棱瓜子。收集到核心药组56个活性成分,作用于47个关键靶点,预测出1194条生物过程、49个细胞组成、54个分子功能以及226条信号通路。结论 藏医在治疗肝胆疾病中主要以“清赤巴热”为核心,所使用方剂中的药物多以苦味为主;核心药组治疗肝胆疾病可能是通过缓解体内氧化应激、降低炎症表达以及调节胆汁酸肝肠循环等作用机制。 相似文献